- Home
- STTK vs BCG Comparison
STTK vs BCG Comparison
Compare STTK & BCG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STTK
- BCG
- Stock Information
- Founded
- STTK 2016
- BCG 2016
- Country
- STTK United States
- BCG United States
- Employees
- STTK N/A
- BCG N/A
- Industry
- STTK Biotechnology: Pharmaceutical Preparations
- BCG
- Sector
- STTK Health Care
- BCG
- Exchange
- STTK Nasdaq
- BCG Nasdaq
- Market Cap
- STTK 37.6M
- BCG 41.3M
- IPO Year
- STTK 2020
- BCG N/A
- Fundamental
- Price
- STTK $0.83
- BCG $2.07
- Analyst Decision
- STTK Hold
- BCG
- Analyst Count
- STTK 4
- BCG 0
- Target Price
- STTK $3.00
- BCG N/A
- AVG Volume (30 Days)
- STTK 401.8K
- BCG 9.1K
- Earning Date
- STTK 07-31-2025
- BCG 08-14-2025
- Dividend Yield
- STTK N/A
- BCG N/A
- EPS Growth
- STTK N/A
- BCG N/A
- EPS
- STTK N/A
- BCG N/A
- Revenue
- STTK $4,606,000.00
- BCG $172,860,000.00
- Revenue This Year
- STTK N/A
- BCG N/A
- Revenue Next Year
- STTK N/A
- BCG N/A
- P/E Ratio
- STTK N/A
- BCG N/A
- Revenue Growth
- STTK 69.65
- BCG 7.36
- 52 Week Low
- STTK $0.69
- BCG $1.71
- 52 Week High
- STTK $4.99
- BCG $6.55
- Technical
- Relative Strength Index (RSI)
- STTK 39.19
- BCG N/A
- Support Level
- STTK $0.77
- BCG N/A
- Resistance Level
- STTK $0.91
- BCG N/A
- Average True Range (ATR)
- STTK 0.08
- BCG 0.00
- MACD
- STTK -0.02
- BCG 0.00
- Stochastic Oscillator
- STTK 16.23
- BCG 0.00
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
About BCG Binah Capital Group Inc. Common Stock
Binah Capital Group Inc formerly Wentworth Management Services LLC is a holding company that acquires and manages businesses in the wealth management industry. The company specializes in consolidating independent broker-dealers to capture economies of scale needed to service financial advisors in today's technology-enabled regulatory environment. Wentworth's core philosophy focuses on building long-term, productive relationships with its advisor base.